PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06. Dezember 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET
03. Dezember 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
14. November 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time
06. November 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
22. Oktober 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
02. Oktober 2024 08:00 ET
|
PDS Biotechnology Corporation
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8)88% (15/17) of patients had a complete...
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
16. September 2024 07:00 ET
|
PDS Biotechnology Corporation
Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage VERSATILE-003 Phase 3...
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
09. September 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
03. September 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results
13. August 2024 08:00 ET
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...